PSC-PEG2-TOC (VMT-α-NET) is a somatostatin receptor subtype 2 (SSTR2) targeting peptide of very high stability for the treatment of neuroendocrine tumours (NET) that shows rapid tumour accumulation, high tumour retention and fast renal excretion (Li et al. 2023). This evidence concerns the gene SSTR2 and neoplasm.